who should avoid glp 1 There was a lot of conversation about Medicare and GLP-1 medications last week, and I understand why. For so many people, the biggest barrier to evidence-based treatment has never been lack of GLP-1 Weight-Loss Medication Glucagon-like peptide-1

477,478,479 If this is indeed the case, then both types of heart failure are syndromes caused by multiple metabolic and inflammatory changes

Oral GLP-1 RAs are also under development, and early data show similar weight loss efficacy to semaglutide 2.4 mg [84], which could improve convenience and potentially reduce costs through improved manufacturing and distribution efficiency

At the same time, a few states expanded access (Missouri, Tennessee, and Utah), reflecting competing pressures between clinical demand and budgets

Gastrointestinal reactions and digestive issues are linked to Ozempic use, including upset stomach (dyspepsia), burping (eructation), gas (flatulence) and gastroesophageal reflux disease

So this is a growing threat that I think needs to be monitored closely. If GLP-1s do become prohibited, athletes could theoretically apply for a therapeutic use exemption (TUE), which allows them to take a drug if it is treating a legitimate medical condition, and does not meaningfully enhance their performance